LRPAP1 and glioma: To explain the discrepancy between MYXV therapy for gliomas and GBCs in vivo as well as how MYXV + Rap effectively killed GBCs in vitro but not in vivo, we hypothesized that tumor-associated ECM may be different between the 2 tumor types.